Xilio Therapeutics (NASDAQ:XLO) today reported its financial results for the fourth quarter and full year ended December 31, 2025, detailing a year of disciplined platform validation and pipeline expansion.
The company, which specializes in "tumor-activated" immuno-oncology (IO) therapies designed to minimize systemic toxicity, enters 2026 with $137.5 million in cash and cash equivalents.
This capital position provides a comfortable operational runway through the end of 2027, encompassing several high-impact clinical readouts.
The primary focus for the first half of 2026 is the advancement of XTX501, Xilio’s masked, tumor-activated IL-2 candidate.
Management confirmed plans to submit an Investigational New Drug (IND) application in mid-2026, with a Phase 1 clinical trial expected to commence in the second half of the year.
Unlike traditional IL-2 therapies, which are often hindered by severe side effects, XTX501 is engineered to remain inactive in healthy tissue and "unmask" specifically within the tumor microenvironment, potentially offering a significantly wider therapeutic window.
In addition to its lead programs, Xilio is diversifying its portfolio with a focus on multi-specific modalities.
The company expects to nominate a development candidate for its new multi-specific masked T-cell engager in the second quarter of 2026, leveraging its masking technology to guide immune cells more precisely toward solid tumors.
Furthermore, Xilio will present new data for its tumor-activated CLDN18.2 program at the American Association for Cancer Research (AACR) Annual Meeting in April 2026, targeting a marker with significant industry momentum in gastric and pancreatic cancers.